Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

Abstract

BACKGROUND: Prostate cancer is the most common cancer and secondleading cause of cancer death among men in the United States. Prostate cancer poses a large economic burden, which increases with progression from localized to metastatic disease. Newly approved treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC) delay disease progression and reduce the risk of metastatic disease. Quantifying the potential budget impact of these new treatments is of interest to health care decision makers. OBJECTIVE: To estimate the budget impact of enzalutamide for the treatment of patients with nmCRPC in the United States over a 3-year time horizon.METHODS: An Excel-based model was developed to estimate the budget impact to a U.S. health plan of enzalutamide, a second-generation antiandrogen, as an add-on to androgen deprivation therapy (ADT) for the treatment of high-risk nmCRPC patients (prostate-specific antigen doubling time of ≤ 10 months). Comparators include apalutamide + ADT, bicalutamide + ADT, and ADT only. The analysis includes treatment costs for nmCRPC and for treatment after progression to metastatic castration-resistant prostate cancer (mCRPC). The treated population size was estimated from epidemiological data and literature. Dosing, duration of therapy, and adverse event rates were based on package inserts and pivotal studies. RED BOOK, Centers for Medicare & Medicaid Services fee schedules, and literature were used to obtain costs of drugs, adverse events, and health care visits. Market shares were estimated for each comparator before and after enzalutamide adoption. A 1-way sensitivity analysis was performed to quantify the impact of parameter uncertainty. RESULTS: In a hypothetical 1-million-member plan with 3% annual growth, it was estimated that there would be approximately 19 eligible incident nmCRPC patients in year 1, increasing to 20 eligible incident patients in year 3.

A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents

“…This is a relevant aspect that needs to be taken into account in specific high-quality cost-effectiveness analyses based on randomized controlled trials to balance early treatment healthcare costs, benefits of delaying disease progression, treatment adverse events, and QoL. These types of analysis have the purpose to avoid unfavorable patients' outcomes and unjustified healthcare system costs considering quality-adjusted life-year gained/life-year saved [33,34].…”

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA

“…One-way sensitivity analyses (OWSAs) were performed to quantify the impact in response to changes in key variables (OSM Table 9; i.e., changes in treatment persistence, number of incontinence episodes, CYP2D6-related drug-drug interactions, cost of comorbidities, and cost of AEs). OWSAs were run with an input variable set to either its low (20% decrease) or its high (20% increase) value (a range commonly used in BIMs; for a recent example, see Schultz et al [26]), while the remaining variables remained unchanged. Findings from the OWSAs are summarized in tornado diagrams in terms of the PMPM.…”

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer

“…Sample data were collected from 75 oncologists and to metastatic disease each year. 15 The percentage of patients who left the population each year was not applied to the incident cases in the model year, and patients who left the target population in a given year were excluded from the starting population in the following year.…”